Skip to main content
Top
Published in: BMC Ophthalmology 1/2014

Open Access 01-12-2014 | Case report

Intraoperative and fluorescein angiographic findings of a secondary macular hole associated with age-related macular degeneration treated by pars plana vitrectomy

Authors: Tomohiro Okamoto, Hajime Shinoda, Toshihide Kurihara, Norihiro Nagai, Kazuo Tsubota, Yoko Ozawa

Published in: BMC Ophthalmology | Issue 1/2014

Login to get access

Abstract

Background

Macular hole results from a tractional force at the vitreo-retinal interface which is developed by modification and subsequent degeneration of the posterior precortical vitreous and the internal limiting membrane (ILM). Meanwhile, the wet type of age-related macular degeneration (AMD) is caused by the submacular formation of choroidal neovascularization (CNV). Although exudative changes derived from CNV may cause epiretinal membrane (ERM) formation, which can also cause tractional force at the vitreo-retinal interface, there have been few reports of AMD-associated macular hole development in which the full thickness of the retinal tissue is completely torn by the tractional force. Moreover, intraoperative finding of macular hole associated with AMD with a possible involvement of subretinal lesion has not been described.

Case presentation

A 78-year-old man diagnosed with wet AMD with subretinal fluid and mild cataract received 8 treatments with intravitreal pegaptanib. After AMD remission, he developed a secondary macular hole in the same eye. He underwent a pars plana vitrectomy that successfully closed the macular hole. Intraoperatively, it was found that the patient’s vitreous was formed and that the ERM and ILM were adherent, suggesting the involvement of a tractional force at the vitreo-retinal interface due to an inflammatory reaction related to AMD and/or intravitreally injected chemical compounds, resulting in macular hole development. Changes in the condition of his AMD and the RPE were observed on a fluorescein angiogram (FA) and an indocyanine green angiogram (IA) that preceded macular hole development, suggesting that subretinal changes may also have been involved in the pathogenesis.

Conclusion

These clinical data, including the intraoperative findings and the temporal changes in the angiograms, suggest that an inflammatory reaction at the vitreo-retinal interface and subretinal lesion related to AMD contribute to the macular hole development in AMD patients treated with intravitreal injection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kishi S, Shimizu K: Posterior precortical vitreous pocket. Arch Ophthalmol. 1990, 108 (7): 979-982. 10.1001/archopht.1990.01070090081044.CrossRefPubMed Kishi S, Shimizu K: Posterior precortical vitreous pocket. Arch Ophthalmol. 1990, 108 (7): 979-982. 10.1001/archopht.1990.01070090081044.CrossRefPubMed
2.
go back to reference Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S: Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol. 2000, 118 (8): 1116-1118. 10.1001/archopht.118.8.1116.CrossRefPubMed Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S: Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol. 2000, 118 (8): 1116-1118. 10.1001/archopht.118.8.1116.CrossRefPubMed
3.
go back to reference Park DW, Sipperley JO, Sneed SR, Dugel PU, Jacobsen J: Macular hole surgery with internal-limiting membrane peeling and intravitreous air. Ophthalmology. 1999, 106 (7): 1392-1397. 10.1016/S0161-6420(99)00730-7.CrossRefPubMed Park DW, Sipperley JO, Sneed SR, Dugel PU, Jacobsen J: Macular hole surgery with internal-limiting membrane peeling and intravitreous air. Ophthalmology. 1999, 106 (7): 1392-1397. 10.1016/S0161-6420(99)00730-7.CrossRefPubMed
4.
go back to reference Sakamoto T, Ishibashi T: Visualizing vitreous in vitrectomy by triamcinolone. Graefes Arch Clin Exp Ophthalmol. 2009, 247 (9): 1153-1163. 10.1007/s00417-009-1118-2.CrossRefPubMed Sakamoto T, Ishibashi T: Visualizing vitreous in vitrectomy by triamcinolone. Graefes Arch Clin Exp Ophthalmol. 2009, 247 (9): 1153-1163. 10.1007/s00417-009-1118-2.CrossRefPubMed
5.
go back to reference Spiteri Cornish K, Lois N, Scott NW, Burr J, Cook J, Boachie C, Tadayoni R, la Cour M, Christensen U, Kwok AK: Vitrectomy with internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole. Ophthalmology. 2014, 121 (3): 649-655. 10.1016/j.ophtha.2013.10.020.CrossRefPubMed Spiteri Cornish K, Lois N, Scott NW, Burr J, Cook J, Boachie C, Tadayoni R, la Cour M, Christensen U, Kwok AK: Vitrectomy with internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole. Ophthalmology. 2014, 121 (3): 649-655. 10.1016/j.ophtha.2013.10.020.CrossRefPubMed
6.
go back to reference Steel DH, Lotery AJ: Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye. 2013, 27 (1): 212- Steel DH, Lotery AJ: Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye. 2013, 27 (1): 212-
7.
go back to reference Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004, 122 (4): 564-572.CrossRefPubMed Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004, 122 (4): 564-572.CrossRefPubMed
8.
go back to reference Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004, 351 (27): 2805-2816. 10.1056/NEJMoa042760.CrossRefPubMed Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004, 351 (27): 2805-2816. 10.1056/NEJMoa042760.CrossRefPubMed
9.
go back to reference Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355 (14): 1432-1444. 10.1056/NEJMoa062655.CrossRefPubMed Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355 (14): 1432-1444. 10.1056/NEJMoa062655.CrossRefPubMed
10.
go back to reference Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012, 119 (12): 2537-2548. 10.1016/j.ophtha.2012.09.006.CrossRefPubMed Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012, 119 (12): 2537-2548. 10.1016/j.ophtha.2012.09.006.CrossRefPubMed
11.
go back to reference Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N: Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005, 112 (6): 1048-1053. 10.1016/j.ophtha.2005.01.043.CrossRefPubMed Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N: Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005, 112 (6): 1048-1053. 10.1016/j.ophtha.2005.01.043.CrossRefPubMed
12.
go back to reference Chang LK, Sarraf D: Tears of the retinal pigment epithelium: an old problem in a new era. Retina. 2007, 27 (5): 523-534. 10.1097/IAE.0b013e3180a032db.CrossRefPubMed Chang LK, Sarraf D: Tears of the retinal pigment epithelium: an old problem in a new era. Retina. 2007, 27 (5): 523-534. 10.1097/IAE.0b013e3180a032db.CrossRefPubMed
13.
go back to reference Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P: Symptomatic vitreomacular adhesion. Retina. 2013, 33 (8): 1503-1511. 10.1097/IAE.0b013e31829232fd.CrossRefPubMed Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P: Symptomatic vitreomacular adhesion. Retina. 2013, 33 (8): 1503-1511. 10.1097/IAE.0b013e31829232fd.CrossRefPubMed
14.
go back to reference Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U: Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009, 116 (12): 2393-2399. 10.1016/j.ophtha.2009.05.039.CrossRefPubMed Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U: Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009, 116 (12): 2393-2399. 10.1016/j.ophtha.2009.05.039.CrossRefPubMed
15.
go back to reference Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005, 46 (2): 726-733. 10.1167/iovs.04-0601.CrossRefPubMed Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005, 46 (2): 726-733. 10.1167/iovs.04-0601.CrossRefPubMed
16.
go back to reference Querques G, Souied EH, Soubrane G: Macular hole following intravitrealranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol Scand. 2009, 87 (2): 235-237.CrossRef Querques G, Souied EH, Soubrane G: Macular hole following intravitrealranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol Scand. 2009, 87 (2): 235-237.CrossRef
Metadata
Title
Intraoperative and fluorescein angiographic findings of a secondary macular hole associated with age-related macular degeneration treated by pars plana vitrectomy
Authors
Tomohiro Okamoto
Hajime Shinoda
Toshihide Kurihara
Norihiro Nagai
Kazuo Tsubota
Yoko Ozawa
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2014
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/1471-2415-14-114

Other articles of this Issue 1/2014

BMC Ophthalmology 1/2014 Go to the issue